Teva targets schizophrenia to build on innovative medicines growth

In 2023, the pharma giant won an FDA nod for its schizophrenia drug Uzedy, which pulled in higher-than-expected revenue of $117 million last year. Rather than offering patients a new molecule, Uzedy’s breakthrough is tied to its method of delivery.